Biohaven Ltd. (NYSE:BHVN) Given Average Rating of “Buy” by Brokerages

Shares of Biohaven Ltd. (NYSE:BHVNGet Free Report) have earned a consensus rating of “Buy” from the eight analysts that are covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $52.00.

A number of analysts have recently issued reports on the stock. HC Wainwright lifted their price objective on shares of Biohaven from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, March 4th. UBS Group assumed coverage on shares of Biohaven in a research report on Tuesday, February 6th. They issued a “buy” rating and a $59.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research report on Thursday. JPMorgan Chase & Co. lifted their target price on shares of Biohaven from $32.00 to $56.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, TD Cowen lifted their target price on shares of Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a research report on Friday, March 1st.

Check Out Our Latest Stock Analysis on BHVN

Hedge Funds Weigh In On Biohaven

A number of hedge funds have recently modified their holdings of BHVN. US Bancorp DE increased its position in shares of Biohaven by 19.1% during the first quarter. US Bancorp DE now owns 586 shares of the company’s stock valued at $70,000 after buying an additional 94 shares during the period. KBC Group NV bought a new stake in Biohaven during the fourth quarter worth about $74,000. Advisor Group Holdings Inc. boosted its stake in Biohaven by 219.8% during the fourth quarter. Advisor Group Holdings Inc. now owns 8,606 shares of the company’s stock worth $120,000 after acquiring an additional 5,915 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new stake in Biohaven during the first quarter worth about $143,000. Finally, Creative Planning bought a new stake in Biohaven during the fourth quarter worth about $147,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Stock Performance

NYSE BHVN opened at $38.99 on Friday. Biohaven has a 52-week low of $12.35 and a 52-week high of $62.21. The company has a market capitalization of $3.19 billion, a P/E ratio of -6.89 and a beta of 1.18. The company has a fifty day moving average of $51.84 and a 200-day moving average of $41.47.

Biohaven (NYSE:BHVNGet Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). As a group, analysts forecast that Biohaven will post -5.85 EPS for the current fiscal year.

Biohaven Company Profile

(Get Free Report

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

Recommended Stories

Analyst Recommendations for Biohaven (NYSE:BHVN)

Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.